Immediate Recommendation for CNS Lesion Workup and Safe LP
Proceed with lumbar puncture using aggressive platelet support (target ≥50 × 10⁹/L) to obtain CSF for comprehensive infectious workup and cytology/flow cytometry, as distinguishing CNS infection from myeloma relapse is critical and cannot be achieved through imaging alone in this post-CAR-T patient with new enhancing brain lesions.
Rationale for Prioritizing LP Despite Thrombocytopenia
Your patient's five new punctate enhancing brain lesions demand tissue or CSF diagnosis. While the lesions are too small for stereotactic biopsy, LP remains feasible with appropriate platelet support. The FDA label for romiplostim (Nplate) demonstrates that platelet counts can be rapidly increased with dose escalation 1. Given your patient is already on weekly Nplate, consider:
- Increase Nplate dose (current regimen appears suboptimal given persistent PLT ~22K)
- Administer platelet transfusions immediately pre-LP targeting ≥50 × 10⁹/L
- Consider additional platelet transfusion available at bedside during procedure
- Use smallest gauge needle (22G or smaller) with experienced operator
The risk-benefit strongly favors LP: untreated CNS infection (particularly fungal) in this immunocompromised host carries near-certain mortality, whereas LP-related hemorrhage risk is manageable with platelet support.
Distinguishing CNS Myeloma from Infection
CSF Studies to Order:
Infectious workup (priority):
- Fungal culture, cryptococcal antigen, (1→3)-β-D-glucan
- Bacterial culture and Gram stain
- CMV PCR, HHV-6 PCR, EBV PCR, VZV PCR
- Toxoplasma PCR
- Acid-fast bacilli culture and PCR
Myeloma assessment:
- Flow cytometry for clonal plasma cells
- Cytology with immunohistochemistry
- Protein electrophoresis with immunofixation
- Kappa/lambda free light chains
Why Infection is More Likely Than CNS Myeloma:
Systemic myeloma remains in complete response by bone marrow biopsy and serum markers—isolated CNS progression without systemic relapse is exceedingly rare in MM 2
Post-BCMA CAR-T infectious risk is substantial: CMV reactivation occurs in 20% of MM patients post-BCMA CAR-T, though most are asymptomatic 3. Your patient has documented CMV viremia (667 IU/mL) and prior HHV-6 detection, indicating ongoing immune dysfunction
Prior hypervascular hepatic/splenic lesions raise concern for disseminated fungal infection (Candida, Aspergillus, or endemic fungi)
Persistent severe cytopenias reflect ongoing immune compromise—grade ≥3 thrombocytopenia post-BCMA CAR-T is associated with worse outcomes and prolonged immune dysfunction 4, 5, 6
Systemic Myeloma Restaging
Complete restaging with PET/CT is warranted despite bone marrow showing complete response. The 2024 EANM guidelines recommend FDG-PET/CT for suspected relapse to detect extramedullary disease and distinguish active from inactive lesions 7. Your pending CT chest/abdomen/pelvis should be upgraded to whole-body PET/CT to:
- Assess the hepatic/splenic lesions for metabolic activity
- Identify potential biopsy targets outside the CNS
- Rule out occult systemic myeloma relapse
- Evaluate for disseminated infection
If PET/CT shows FDG-avid hepatic or splenic lesions, image-guided biopsy of these sites may be safer than CNS biopsy and could establish diagnosis.
CMV Management
Your patient's CMV PCR of 667 IU/mL is clinically significant in this context. While most CMV reactivations post-BCMA CAR-T are asymptomatic 3, 8, CNS symptoms with new brain lesions change the calculus. Restart CMV-directed therapy despite prior maribavir intolerance:
- First-line: Valganciclovir 900 mg PO BID (adjust for renal function)
- If GI intolerance: IV ganciclovir 5 mg/kg IV Q12H
- Alternative: Foscarnet 90 mg/kg IV Q12H (if marrow toxicity prohibitive)
The risk of CMV encephalitis or disseminated disease outweighs GI side effects. Coordinate with ID regarding optimal agent selection.
Thrombocytopenia Management
Your patient's persistent severe thrombocytopenia is multifactorial but primarily reflects post-BCMA CAR-T hematotoxicity. Thrombocytopenia occurs in 45-60% of MM patients post-BCMA CAR-T, with delayed recovery common 5, 6. Grade ≥3 thrombocytopenia is associated with shorter overall survival 4.
Optimize Nplate dosing:
- Current weekly dosing appears inadequate
- FDA label supports dose escalation up to 10 mcg/kg weekly 1
- Consider increasing frequency to twice weekly if weekly escalation insufficient
- Peak platelet response occurs 7-14 days post-dose 1
Rule out secondary causes:
- Your TMA workup is appropriately negative
- Consider bone marrow biopsy if not recently done to assess:
- Marrow cellularity and megakaryocyte numbers
- Exclude therapy-related MDS (t-MDS can present as persistent cytopenia post-CAR-T) 9
- Rule out marrow infiltration by infection or occult myeloma
HLH Surveillance
Your prior HLH history and current ferritin of 1,919 warrant continued vigilance. Check:
- Soluble IL-2 receptor (already pending—appropriate)
- Repeat triglycerides and fibrinogen serially
- NK cell function if HLH suspected
Fever, cytopenias, and ferritin elevation could represent HLH recurrence, though current fibrinogen (343) and triglycerides (176) are reassuring.
Empiric Antimicrobial Coverage
While awaiting CSF results, broaden empiric coverage:
Current cefepime is appropriate for bacterial coverage
Add empiric antifungal therapy immediately:
- Liposomal amphotericin B 5 mg/kg IV daily (preferred for CNS penetration and broad fungal coverage including Aspergillus, Candida, Cryptococcus, endemic fungi)
- Alternative: Voriconazole 6 mg/kg IV Q12H × 2 doses, then 4 mg/kg Q12H (if Aspergillus primary concern, but check drug interactions)
Restart CMV therapy as discussed above
Continue acyclovir and Bactrim for prophylaxis
Neurology and Ophthalmology Consultation
Neurology consultation should focus on:
- Seizure risk assessment (consider prophylactic levetiracetam given multiple cortical lesions)
- Optimal timing and technique for LP
- Need for repeat MRI with contrast to assess lesion evolution
Ophthalmology slit-lamp and dilated funduscopic exam to evaluate for:
- CMV retinitis
- Fungal endophthalmitis
- Toxoplasma chorioretinitis
Summary Algorithm
- Escalate Nplate dose and transfuse platelets to ≥50 × 10⁹/L
- Perform LP with comprehensive infectious and myeloma CSF studies
- Obtain whole-body PET/CT for systemic restaging and biopsy target identification
- Initiate empiric liposomal amphotericin B and restart CMV-directed therapy
- Pursue hepatic/splenic lesion biopsy if PET-avid and accessible
- Consider bone marrow biopsy if thrombocytopenia persists despite Nplate optimization
- Neurology and ophthalmology consultations for comprehensive CNS/ocular assessment
The key pitfall to avoid is delaying LP due to thrombocytopenia—with appropriate platelet support, the procedure is feasible and diagnostically essential. Empiric broad-spectrum antimicrobials should not delay LP but should be initiated immediately given high mortality risk of untreated CNS infection in this profoundly immunocompromised patient 3, 10.